Description

Axogen Raises Its Revenue Outlook to at Least $279 Million But Does It Deserve An Upgrade?

Axogen, Inc. reported second quarter 2026 revenue of $69.7 million, reflecting a 23.1% increase compared to the same quarter last year. This growth was broad-based across its three primary target markets: Extremities, Oral Maxillofacial (OMF) & Head and Neck, and Breast. The Breast segment showed particular strength, with first-half 2026 revenue up 47% year-over-year and contributing roughly two-thirds of the quarter’s incremental growth. Extremities and OMF & Head and Neck markets combined delivered steady 15% year-over-year growth, underscoring ongoing adoption of Axogen’s nerve care technologies. The company’s adjusted net income for the quarter was $7.3 million, with adjusted EBITDA of $8.4 million, while gross margin decreased to 72.7% from 74.2% in the prior year quarter. This decline was primarily due to product mix changes, driven by faster-than-anticipated growth in the Breast market, which involves longer Avance grafts carrying higher production costs.